We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Neurology

Influence of Parity on Cognitive Decline and Hippocampal Atrophy in Amyloid-Positive Postmenopausal Women

MedXY Editorial Team•Aug 18, 2026•Neurology
Parityβ-Amyloidhippocampal volumecognitive declineAlzheimer's disease

Highlight

• Higher parity interacts with amyloid pathology to exacerbate cognitive decline in cognitively unimpaired postmenopausal women.
• Women with positive CSF β-amyloid biomarkers and greater parity show reduced hippocampal volume over time.
• Parity may influence brain resilience to Alzheimer’s disease (AD) pathology in preclinical stages.
• These findings have implications for understanding sex-specific factors affecting AD progression.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Arterial Spin Labeling Hemodynamic Metrics Predict Cognitive Decline and Small Vessel Disease Progression Over 11 YearsThis study demonstrates that arterial spin labeling spatial coefficient of variation (ASL-sCoV) correlates with cerebral small vessel disease burden and predicts cognitive decline over 11 years, outperforming traditional cerebral blood flowSep 19, 2026Early Life Vascular Risk and Midlife Markers of Brain Aging: Insights from Longitudinal Neuroimaging and Cognitive Trajectory StudiesThis review synthesizes longitudinal evidence linking early adulthood vascular risks, particularly elevated systolic blood pressure and smoking, to midlife cognitive decline and brain structural alterations. It highlights critical interventSep 17, 2026Integrating Plasma p-tau217 and APOE Genotype to Predict Cognitive Decline Across Diverse PopulationsThis pooled analysis of seven multi-ethnic cohorts demonstrates the combined prognostic value of plasma phosphorylated tau 217 concentrations and APOE-ε4 genotype for predicting risk and timing of cognitive impairment, emphasizing biomarkerSep 13, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
CSF Biomarkers as Indicators of Disease Severity in Probable Cerebral Amyloid Angiopathy: Insights Beyond MRI
This study demonstrates that cerebrospinal fluid beta-amyloid peptides correlate with MRI markers of disease severity in probable cerebral amyloid angiopathy, suggesting CSF biomarkers provide a direct measure of vascular amyloid burden, in
Sep 6, 2026
Unraveling Alzheimer’s Disease Progression in Down Syndrome via Blood Proteome DynamicsLongitudinal analysis of blood proteins reveals distinctive trajectories and associations with cognitive decline in adults with Down syndrome, shedding light on Alzheimer’s disease pathophysiology in this high-risk group.Sep 5, 2026
Association of Clonal Hematopoiesis With Silent Brain Lesions and Cognitive Decline in Patients With Atrial Fibrillation: An Integrative ReviewClonal hematopoiesis (CHIP) significantly associates with increased silent brain lesions and progressive cognitive decline in atrial fibrillation patients, highlighting a novel neurovascular risk factor with implications for patient managemAug 24, 2026